Form 4: Vertex Pharmaceuticals EVP, COO Stuart A. Arbuckle Reports Changes in Beneficial Ownership

Stuart A. Arbuckle, EVP and COO of Vertex Pharmaceuticals, reports the acquisition of 37,622 shares of common stock and disposal of 140 shares due to performance stock unit vesting.

Summary

• On May 13, 2025, Stuart A. Arbuckle, the EVP and COO of Vertex Pharmaceuticals, reported changes in beneficial ownership of the company's stock.
• Arbuckle acquired 37,622 shares of common stock related to a performance stock unit award granted on December 6, 2022, at a price of $0 per share.
• The performance-vesting requirements were certified by the issuer's management development and compensation committee on May 13, 2025, and the shares will vest on July 1, 2025.
• Arbuckle also disposed of 140 shares of common stock.
• Following these transactions, Arbuckle directly owns 100,611 shares of Vertex Pharmaceuticals common stock and indirectly owns 140 shares through a 401(k).

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects routine executive compensation and stock ownership changes. The acquisition of shares due to performance goals being met is mildly positive.

Positives

• The acquisition of shares indicates that performance goals were met, which could be viewed positively.

Negatives

• The disposal of 140 shares could be seen as a minor negative, although it's a small amount compared to the acquisition.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.

Stakeholder Impact

• The vesting of performance stock units aligns executive interests with shareholder value.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Stuart A. Arbuckle, EVP, COO, Beneficial Ownership, Performance Stock Units, Stock Acquisition, Stock Disposal, Form 4